ArticleCancers2023

First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.

Vineeth Tatineni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.